Virus Filtration Market – Growth, Latest Trend & Forecast

In 2022, global virus filtration system sales reached a substantial US$ 4 billion. The market is poised for significant growth, with a projected CAGR of 13% to reach US$ 6.5 billion by 2026. This growth is fueled by the increasing prevalence of diseases such as cancer, diabetes, contagious infections like COVID-19, and autoimmune disorders. Between 2022 and 2026, the virus filtration market (ウイルスろ過市場) is expected to expand tremendously.

For Critical Insights on Virus Filtration Market, Request a Sample Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=7611

According to WHO estimates, cancer was responsible for approximately 10 million deaths worldwide in 2020. Additionally, in low- and lower-middle-income countries, diseases such as hepatitis and human papillomavirus (HPV) contribute to around 30% of cancer cases.

Virus filtration employs a membrane barrier to trap virus particles, serving as the primary defense against invasive viruses. Pharmaceutical companies are increasingly focusing on virus filtration to ensure the safety of biopharmaceutical products, leading to significant investments in new technologies. North America and Europe are expected to be key markets for virus filtration.

Key Takeaways from Virus Filtration Market Study

• North America holds a leading position in the virus filtration market (바이러스 여과 시장) due to the presence of key players and advanced healthcare infrastructure.
• The global market for virus filtration systems is currently valued at US$ 4 billion.
• Demand for virus filtration devices is expected to expand at a CAGR of 13% from 2022 to 2026.
• The kits & reagents segment is expected to expand at an impressive CAGR of 15% from 2022-2026

The rapid growth in demand for biopharmaceutical products is a major driver of the global virus filtration market. The continued use of these products relies on their high efficacy and minimal side effects in treating diseases and conditions, rather than just alleviating symptoms. Over the next four years, rapid technological advancements and the increased adoption of single-use technology are expected to further drive market expansion.

The kits & reagents segment is expected to expand at an impressive CAGR of 15% from 2022-2026. In the viral filtration industry, kits & reagents are a very significant segment. The reagents aid in lowering the chance of iatrogenic viral transmission. The reagents aid in determining the virus that is most likely to infect the cell substrate or any other reagents or components employed in the procedure when evaluating the process.

Key Players

• Abbott Laboratories
• Asahi Kasei Medical Co., Ltd.
• BioMérieux SA
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Hologic, Inc.
• Lonza Group AG
• Pall Corporation
• QIAGEN
• Sartorius AG
• Thermo Fisher Scientific Inc.
• WuXi Biologics

Competitive Landscape

According to the competitive environment in the global viral filtration market, key industry players are likely to prioritize both, organic and inorganic tactics, such as product launches, mergers and acquisitions, R&D initiatives, and innovations.

BioProcess International, General Electric, WuXi AppTec, Synder Filtration, Inc., Asahi Kasei Medical Co., Ltd., Danaher, Sotera Health, BIA Separations, Sartorius AG, Lonza, and Merck KGaA are a few of the top businesses in the market.

To co-develop and co-commercialize the therapeutic candidate Bintrafusp alfa, Merck and a subsidiary of GSK agreed on a global partnership in the field of immuno-oncology in February 2019.

Merck and Artios Pharma Limited announced their collaborative agreement to find and develop multiple-precision oncology treatments, in 2020.

SenzaGen and Charles River Laboratories, one of the top providers of laboratory services globally, renewed and expanded their global partnership agreement in January 2021. The agreement was expanded to include all tests in the GARD portfolio to fulfil the rising demand for risk assessment of chemicals utilizing SenzaGen's non-animal test platform GARD.

Lonza and Moderna, a biotechnology business that invented messenger RNA treatments and vaccines, announced their partnership in June 2021. The extended agreement will allow for more COVID-19 Vaccine Moderna medicinal substance manufacturing. At Lonza's Geleen facility, a new manufacturing line for the synthesis of drug substances will be made available.

Get Customization on Virus Filtration Market Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7611

Segmentation of Virus Filtration (Markt für Virenfilterung) Industry Research Report

• By Type :

  • Kits & Reagents

  • Services

  • Filtration Systems

  • Others

• By Application :

  • Biological

  • Medical Devices

  • Water Purification

  • Air Purification

  • Others

• By End User :

  • Pharmaceutical & Biotechnology Companies

  • Contract Research Organizations

  • Academic Research Institutes

  • Medical Device Companies

  • Others

• By Region :

  • North America

  • Latin America

  • Europe

  • East Asia

  • South Asia & Oceania

  • MEA

About Fact.MR :

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.

Contact:

US Sales Office

11140 Rockville Pike

Suite 400 Rockville, MD 20852

United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: sales@factmr.com